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Background: Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology
of migraine headaches and represents a promising target for migraine treatment. The
humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may
be effective in migraine prophylaxis.
Objectives: The primary objective was to evaluate the safety and tolerability of
single and multiple doses of galcanezumab in humans. Secondary objectives included
assessing the pharmacokinetics and evaluating target engagement.
Methods: A double-blind, randomized, placebo-controlled study (NCT 01337596)
with single escalating and multiple subcutaneous (SC) doses of galcanezumab was
performed in healthy male volunteers. Single doses of 1, 5, 25, 75, 200, and 600 mg of
galcanezumab (n = 7/dose) or placebo (n = 2/dose) were injected SC in six consecutive
cohorts of nine subjects each. One cohort of nine subjects received multiple (4) 150 mg
doses of galcanezumab or placebo every other week. Target engagement was evaluated
by measuring inhibition of capsaicin-induced increase in dermal blood flow (DBF).
Findings: Sixty-three subjects were randomized and included in the safety analyses.
Galcanezumab was well tolerated in single doses (1–600 mg SC) and consecutive
doses (150 mg SC). There was no dose-dependent difference in type or frequency
of treatment-emergent adverse events, and no clinically meaningful difference when
compared with placebo. Pharmacokinetics were linear. Galcanezumab induced a robust,
dose-dependent, and durable inhibition of capsaicin-induced increase in DBF, supporting
the continued clinical development of galcanezumab for prophylaxis in migraine patients.
Keywords: CGRP, dermal blood flow, humanized monoclonal antibody, headache, migraine disorders
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INTRODUCTION
Migraine ranks seventh among disabling disorders and third
in prevalence, accounting for more than half of disabilities
attributable to all neurological diseases (Murray et al., 2012).
Episodic migraine associated with increased frequency of attacks
can progress to chronic migraine (Bigal and Lipton, 2006, 2008;
Lipton, 2011; Diener et al., 2012). Therefore, interruption of
episodic migraine can block its progression to a chronic state.
Calcitonin gene-related peptide (CGRP) is a potent
vasodilatory neuropeptide widely expressed in peripheral
and central neurons (Lennerz et al., 2008; Eftekhari and
Edvinsson, 2011; Warfvinge and Edvinsson, 2013). Considerable
evidence implicates CGRP in the pathophysiology of migraine
(Lassen et al., 2002; Ho et al., 2010; Geppetti et al., 2012; Karsan
and Goadsby, 2015). Intravenous infusion of CGRP precipitated
migraine headache in migraine patients, but not in normal
volunteers (Lassen et al., 2002; Hansen et al., 2010), and CGRP
blood levels were elevated in patients during spontaneous or
nitroglycerin-induced migraine attacks (Goadsby et al., 1988,
1990; Juhasz et al., 2003; Vanmolkot et al., 2006). Sumatriptan
reduced both migraine pain and CGRP blood levels (Juhasz
et al., 2005; Vanmolkot et al., 2006). Imaging studies showed
vasodilation of extracranial, but not intracranial, arteries
ipsilateral to headache during a migraine attack, which were
alleviated by sumatriptan (Asghar et al., 2011; Geppetti et al.,
2012).
Several recent randomized clinical trials with small-molecule
CGRP receptor antagonists, particularly olcegepant and
telcagepant, showed that they effectively abort acute episodic
migraine attacks (Olesen et al., 2004; Ho et al., 2008). Olcegepant
was limited because it could only be formulated and administered
intravenously (Durham and Vause, 2010). Telcagepant produced
pain-free headache responses in acute migraine and decreased
headache frequency with daily administration (Ho et al., 2014).
However, chronic telcagepant therapy was associated with
hepatotoxicity concerns (Ho et al., 2014), most likely related to
the chemical structure of the compound.
The humanized monoclonal antibodies were developed as
an alternative strategy to small-molecule CGRP antagonists for
migraine prophylaxis. Currently there are three monoclonal
antibodies (LY2951742 or galcanezumab, TEV-48125 or
fremanezumab, and ALD-403 or eptinezumab) that bind to
CGRP and 1 (AMG 334 or erenumab) that binds directly to the
CGRP receptor in clinical development (Dodick et al., 2014a,b;
Bigal et al., 2015a,b; Sun et al., 2016). All have proven successful
in reducing the frequency of migraine headaches in early clinical
trials as a preventive therapeutic (Dodick et al., 2014a,b; Bigal
et al., 2015a,b; Sun et al., 2016). Previous studies with small
molecule inhibitors of the CGRP receptor similarly demonstrate
this inhibition is associated with preventing acute attacks (Olesen
et al., 2004; Ho et al., 2008), as well as prevention of attacks (Ho
et al., 2014).
Galcanezumab avidly binds to the human CGRP, with a
binding affinity (KD) of 31 pM (4.5 ng/mL). Galcanezumab
prevented the CGRP-dependent capsaicin-induced increase in
dermal blood flow (DBF) in non-clinical studies with rats
and non-human primates (Vermeersch et al., 2015). Moreover,
galcanezumab inhibited capsaicin-induced vasodilation in non-
human primates for 28 days after single administration,
suggesting a long half-life, making galcanezumab a potentially
valuable therapeutic agent in the prophylaxis of migraine
headache (Vermeersch et al., 2015).
The present report is derived from the first in human dose
Phase I study (NCT 01337596) and presents safety, tolerability,
immunogenicity, and pharmacokinetic (PK) results obtained
with single and multiple subcutaneous injections of up to 600
mg of galcanezumab to healthy male subjects. Additionally, the
study investigated the inhibition by galcanezumab of capsaicin-
induced DBF, which is a validated and well-established method
for evaluating therapeutics targeting the CGRP pathway (Buntinx
et al., 2015). These data guided the modeling of doses for
further clinical trials. Finally, the influence of galcanezumab
on vascular tone was evaluated as an exploratory biomarker.
Although earlier non-clinical studies and clinical experience with
small molecule inhibitors did not suggest a problem (Iovino et al.,
2004; Olesen et al., 2004; Petersen et al., 2005a; Ho et al., 2008,
2014), the potential vascular effects of a therapeutic antibody with
prolonged pharmacologic activity are unknown.
MATERIALS AND METHODS
Study Design
This was a single-center, double-blind, randomized, placebo-
controlled study conducted at the Center for Clinical
Pharmacology of the University Hospitals in Leuven, Belgium
(NCT 01337596). The study involved two sequential parts: a
single-ascending-dose (SAD) phase of six cohorts followed by
onemultiple-dose cohort. Figure 1 includes detailed information
regarding trial conduct and subject randomization for the SAD
part of the study.
In the SAD phase of the study, six cohorts of nine healthymale
subjects each were dosed to assess six dose levels of galcanezumab
administered subcutaneously (SC) in the abdominal wall at doses
of 1, 5, 25, 75, 200, and 600mg (Figure 1). Cohorts were designed
with a sequential single-dose escalation scheme; within each
cohort, seven subjects received galcanezumab and two received
placebo. At each dose level, the first two subjects were dosed
with one subject receiving a single SC dose of galcanezumab
and the other receiving placebo (i.e., sentinel dosing). After an
interval of at least 48 h and following review of all available safety
data [i.e., adverse events (AEs), electrocardiograms (ECGs), vital
signs, and laboratory parameters] of these two sentinel subjects,
the seven remaining subjects were dosed all together. After an
interval of at least 8 days and review of all safety data from all
subjects within each cohort, the next cohort could be dosed with
an increased dose. Subjects were admitted to the research unit
on Day-1, received galcanezumab or placebo SC in the morning
of Day-1, and were discharged on Day 3. Subsequently, they
returned for outpatient visits on Days 5, 8, 14, 28, and 42. For
Cohort 1 subjects (i.e., 1 mg), the final follow-up visit took place
56 days (±2 days) after dosing; for the remaining cohorts, the
final follow-up visit took place 84–129 days after dosing, based
on emerging PK data.
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FIGURE 1 | Disposition of subjects (enrolled subjects).
The multiple-dose cohort started after review of the safety and
tolerability data from the 600 mg single-dose cohort (Figure 1).
In the multiple-dose cohort, nine healthy male subjects were
included to receive a total dose of 600 mg galcanezumab (n = 7)
or placebo (n = 2). Subjects received one SC injection of 150
mg galcanezumab or placebo on Days 1, 15, 29, and 43 in an
alternating site in the abdominal wall (1 injection site per day
with 4 days of injections). The dose of 150 mg was chosen for
two reasons. First, the dose of 150 mg was the maximal dose
that could be administered as a single injection, and therefore,
considered likely a maximum practical dose for assessing the
efficacy in subsequent trials. Further, 150 mg as four injections
did not exceed the maximum dose evaluated as a single dose.
For their first dose, subjects were admitted to the research unit
the evening before dosing (i.e., Day-1); for the remaining doses,
subjects came to the unit on the morning of dosing. Subjects were
discharged approximately 4 h after dosing and returned on an
outpatient basis for scheduled study procedures. The final follow-
up visit of subjects in the multiple-dose cohort was conducted
approximately 4 months after the last dose.
Study Participants
Participants were healthy White males aged between 18 and 55
years inclusive, with a bodymass index (BMI)≥19.0 kg/m2. After
having given written informed consent to participate in the study,
all subjects followed the screening procedures within 30 days
prior to dosing. Each subject participated in only one cohort of
treatment.
The study was conducted following approval by the
independent Ethics Committee of the University Hospitals of
Leuven and in accordance with the Declaration of Helsinki,
the International Conference on Harmonization Good Clinical
Practice guidelines, and local regulations.
Study Assessments
Safety and Tolerability
Subject safety was evaluated on the basis of reported AEs, physical
examination, vital signs (i.e., diastolic blood pressure, systolic
blood pressure, heart rate, and body temperature), ECGs, clinical
chemistry, clinical hematology, and urinalysis. Tolerability was
evaluated by AE reporting. The incidence of AEs was tabulated
using classifications and terms from the Medical Dictionary
for Regulatory Activities (MedDRA; version 14.0). Safety and
tolerability data were collected on an ongoing basis.
Pharmacokinetics
After dosing, serial blood samples were collected for the
determination of serum concentrations and PK parameters of
galcanezumab. Concentration time profiles for galcanezumab
were analyzed using standard non-compartmental methods
of analysis. Area under the curve (AUC) and peak serum
concentration (Cmax) were the primary PK parameters.
Geometric means were estimated, and mixed-effect models
were used to investigate dose proportionality. The apparent
elimination half-life (t1/2) is also reported.
Enzyme-linked immunosorbent assay (ELISA) method was
used for determination of serum levels of galcanezumab.
Pharmacodynamics
The secondary pharmacodynamic (PD) parameters included: (1)
prevention of DBF changes induced by capsaicin as assessed by
laser Doppler imaging (LDI) with the use of a Doppler perfusion
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imager (HR-LDPI system, Periscan PIMII; Perimed, Sweden) and
(2) pulse wave analysis (PWA) for evaluating effects on vascular
tone.
Target engagement (i.e., CGRP binding by galcanezumab)
was evaluated by measuring the inhibition of capsaicin-
induced changes in DBF by galcanezumab. Assessments of DBF
were conducted 48–56 h following dosing and on the days
indicated in Figures 3, 4. The methodology is an established
target engagement biomarker for evaluating CGRP-receptor
antagonists in humans (Van der Schueren et al., 2008; Sinclair
et al., 2010; Buntinx et al., 2015) as well as in monkeys
(Vermeersch et al., 2015).
During the single-dose escalation phase only, the potential
effect of galcanezumab on arterial stiffness (i.e., vascular
tone) was evaluated as an exploratory endpoint. The aortic
augmentation index (AIx@HR75) was used as a measure
of arterial stiffness and derived from radial artery pressure
waveforms. Radial artery pressure waveforms were measured
non-invasively based on tonometry evaluation of the radial artery
as previously reported (Vanmolkot and de Hoon, 2006; Van der
Schueren et al., 2007, 2011). These evaluations were performed at
screening (predose/baseline) and on Days 3, 14, 28, and 42.
Antidrug antibodies (ADA) were determined in serum from
patients by an ELISA assay which determined galcanezumab-
reactive binding proteins after acidification and release of any
bound drug and detection with biotin-labeled galcanezumab.
The assay was validated to be drug tolerant at galcanezumab
concentrations up to 20µg/mL. An initial screening assay was
performed to determine the presence of ADA and then samples
were assayed to determine the titer of ADA. Subsequent, effects
of the presence of ADAs were determined by comparison of PK
and PD in subjects with and without ADA titers.
Statistics
The sample size (seven active and two placebo per cohort)
was determined to be adequate for Phase I studies evaluating
safety and PK parameters and was not powered on the basis of
inferential statistical hypothesis testing. For tables and graphs,
all data from subjects receiving placebo from each cohort are
combined.
Subjects were randomly assigned to galcanezumab or placebo
treatment groups. To that end a computerized randomization
table was prepared by an external statistician and provided to the
study site unblinded pharmacist.
Laboratory parameters, ECGs, and vital signs were
summarized descriptively for each regimen. Laboratory values
and vital signs results were listed. Safety analyses were conducted
for all enrolled subjects who received a dose of study drug,
whether or not they completed all protocol requirements. DBF
and PWA results were listed and summarized using standard
descriptive statistics.
RESULTS
Sixty-three subjects were randomized to study treatments.
During the single-dose-escalation phase, 52 of 54 subjects
completed the study as per protocol. Two subjects received a
single dose of 200 mg galcanezumab but withdrew their consent
for personal reasons prior to completing the final follow-up visit.
As a result, 52 of the 54 subjects randomized in the single-dose-
escalation phase completed the study. During the multiple-dose
part of the study, all nine subjects completed the study as per
protocol. From study drug administration to final follow-up visit,
the study duration for the subjects in the single-dose-escalation
phase varied from 54 to 161 days depending on the dose received.
From study drug administration to final follow-up visit, the study
duration for the subjects in the multiple-dose phase varied from
176 to 181 days. Demographic and baseline characteristics are
presented in Tables 1, 2.
All 63 subjects were included in the safety analyses. All
subjects who received galcanezumab (42 in the single-dose-
escalation phase and seven in the multiple-dose phase) were
included in the PK and PD analyses.
Safety
Galcanezumab was well tolerated in the 1–600 mg dose range
when administered as a single subcutaneous dose and after four
consecutive doses of 150 mg administered over 6 weeks. AEs are
TABLE 1 | Summary of demographic and baseline characteristics of
single-dose-escalation phase.
Dose, mg No. Age,
Year
Weight, kg Height,
cm
BMI,
kg/m2
Placebo 12 30.8
(21–45)
77.73
(66.2–89)
179.3
(163–194)
24.28
(19.8–30.2)
1 7 27.6
(19–46)
75.66
(65.4–88.4)
178.7
(169–190)
23.84
(19.5–29.2)
5 7 29
(19–40)
80.6
(62.6–94.4)
179.3
(167–185)
25.04
(19.8–27.9)
25 7 31.9
(19–54)
75.69
(56.8–87.6)
180.9
(168–187)
23.06
(20.1–25.1)
75 7 30.9
(21–45)
79.03
(71.4–89.2)
180.7
(173–188)
24.27
(20.2–26.9)
200 7 37
(23–54)
91.94
(77.8–108.2)
179.7
(172–186)
28.54
(23.2–34.2)
600 7 33.9
(18–52)
82.8
(65.8–102.2)
178.3
(174–188)
26.04
(21.2–33.8)
Overall 54 31.5
(18–54)
80.24
(56.8–108.2)
179.5
(163–194)
24.94
(19.5–34.2)
Data are presented as mean (range). BMI, body mass index.
TABLE 2 | Summary of demographic and baseline characteristics of
multiple-dose phase.
Parameter Placebo (n = 2) Galcanezumab
600 mg (n = 7)
Overall (N = 9)
Age (year) 22.5 (22–23) 22.4 (21–26) 22.4 (21–26)
Weight (kg) 75.5 (74.2–76.8) 66.4 (51.6–88.8) 68.42 (51.6–88.8)
Height (cm) 182 (179–185) 173.6 (161–186) 175.4 (161–186)
BMI (kg/m2) 22.8 (22.4–23.2) 21.96 (18.5–27.4) 22.14 (18.5–27.4)
Data are presented as mean (range). BMI, body mass index.
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TABLE 3 | Treatment-emergent adverse events experienced by at least one galcanezumab-treated subject after single-dose administration by dose cohort and MedDRA
preferred term.
MedDRA preferred term Galcanezumab dose cohort, mg Placebo (n = 12)
1 (n = 7) 5 (n = 7) 25 (n = 7) 75 (n = 7) 200 (n = 7) 600 (n = 7) Total (n = 42)
At least two TEAEs 6 (86) 5 (71) 7 (100) 4 (57) 7 (100) 5 (71) 34 (81) 9 (75)
Headache 1 (14) 3 (43) 2 (29) 0 (0) 4 (57) 2 (29) 12 (29) 5 (42)
Nasopharyngitis 3 (43) 1 (14) 0 (0) 0 (0) 1 (14) 1 (14) 6 (14) 4 (33)
Dermatitis contact 1 (14) 0 (0) 4 (57) 0 (0) 0 (0) 0 (0) 5 (12) 1 (8)
Diarrhea 0 (0) 0 (0) 1 (14) 1 (14) 1 (14) 1 (14) 4 (10) 0 (0)
Toothache 0 (0) 1 (14) 1 (14) 0 (0) 0 (0) 1 (14) 3 (7) 0 (0)
ALT increased 0 (0) 0 (0) 1 (14) 0 (0) 1 (14) 1 (14) 3 (7) 0 (0)
Hematuria 0 (0) 0 (0) 1 (14) 0 (0) 1 (14) 1 (14) 3 (7) 0 (0)
Dental caries 0 (0) 0 (0) 1 (14) 0 (0) 0 (0) 1 (14) 2 (5) 0 (0)
Vomiting 0 (0) 1 (14) 0 (0) 0 (0) 0 (0) 1 (14) 2 (5) 1 (8)
Injection site hemorrhage 0 (0) 0 (0) 0 (0) 1 (14) 1 (14) 0 (0) 2 (5) 0 (0)
Gastroenteritis 0 (0) 0 (0) 0 (0) 1 (14) 1 (14) 0 (0) 2 (5) 0 (0)
Upper respiratory tract infection 0 (0) 0 (0) 1 (14) 0 (0) 0 (0) 1 (14) 2 (5) 1 (8)
AST increased 0 (0) 1 (14) 1 (14) 0 (0) 0 (0) 0 (0) 2 (5) 0 (0)
Blood CPK increased 0 (0) 1 (14) 1 (14) 0 (0) 0 (0) 0 (0) 2 (5) 0 (0)
Back pain 0 (0) 1 (14) 0 (0) 1 (14) 0 (0) 0 (0) 2 (5) 1 (8)
Leukocyturia 1 (14) 1 (14) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5) 0 (0)
Oropharyngeal pain 0 (0) 1 (14) 0 (0) 1 (14) 0 (0) 0 (0) 2 (5) 0 (0)
Erythema 0 (0) 2 (29) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5) 0 (0)
Pain in extremity 0 (0) 1 (14) 0 (0) 0 (0) 1 (14) 0 (0) 2 (5) 0 (0)
Data are presented as No. (%) of patients experiencing the TEAE. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; MedDRA, Medical
Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.
summarized in Tables 3, 4 for single dose and multiple dose,
respectively. AEs were transient with no apparent relationship
with the prolonged systemic drug exposure (indicated by the long
half-life of galcanezumab). In subjects receiving galcanezumab,
the most common AEs were headache, nasopharyngitis,
hematuria, and contact dermatitis; however, with the exception
of hematuria which was not present in placebo, the frequencies
of these events were similar to placebo. Other frequently reported
AEs in subjects receiving galcanezumabwere diarrhea, toothache,
and increased alanine aminotransferase (ALT). There were no
clinically significant changes from baseline in safety measures in
subjects who received galcanezumab. There were no apparent
differences between galcanezumab dose groups or between
galcanezumab dose groups and placebo in terms of the frequency
of any AEs or changes from baseline in vital signs, laboratory
values, or ECG parameters.
Given the proposed mechanism of action of galcanezumab,
AEs associated with cardiovascular function were of special
interest. Few cardiovascular-related AEs were reported (one
event each in two subjects receiving galcanezumab and one
subject receiving placebo). In the two subjects who received
galcanezumab, the events did not appear to be temporally
associated with dosing of galcanezumab. Increased heart rate was
reported by Subject 1507 (200 mg galcanezumab). This event
occurred 28 days after galcanezumab administration, was mild
in intensity, and was considered not related to galcanezumab.
Subject 1607 experienced an increase in systolic blood pressure
84 days after receiving a single dose of 600 mg galcanezumab.
The Investigator considered the event unlikely to be related to
the study drug. Subject 1105, who received placebo, experienced
an increase in orthostatic heart rate response. Other AEs that
could be potentially related to cardiovascular function included
postural dizziness (reported in one subject each receiving 1
mg galcanezumab and placebo) and presyncope (one subject
receiving placebo). There are no consistent time- or dose-related
effects to consider that galcanezumab was associated with any
cardiovascular effects.
Of additional interest were any particular effects on liver
function. During the single-dose escalation phase, it was noted
that five subjects had transient elevations (i.e., more than
two times the upper normal range) of the hepatic enzymes
aspartate aminotransferase (AST) and ALT. Of these, two
had participated in strenuous physical activity that likely
contributed to the elevations; both were considered by the
Investigator to be unrelated to galcanezumab. The other three
subjects reported 2.7-, 6.5-, and 3.1-fold ALT increases more
than 80 days after receiving a single dose of 5, 200, and
600 mg galcanezumab, respectively. Furthermore, the subject
receiving 200 mg of galcanezumab and presenting with the 6.5-
fold increase in ALT developed liver function abnormalities,
consisting of elevated AST, ALT, alkaline phosphatase, and
(total) bilirubin, typical for acute cholestatic hepatitis at 84
days after dosing with galcanezumab. Given the previously
reported hepatotoxicity associated with the small-molecule
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TABLE 4 | Treatment-emergent adverse events experienced by at least one
galcanezumab-treated subject after multiple-dose administration by MedDRA
preferred term.
MedDRA preferred term Galcanezumab 150 mg
(n = 7)
Placebo (n = 2)
Subjects with at least 1 TEAE 7 (100) 2 (100)
Nasopharyngitis 2 (29) 2 (100)
Injection site pain 2 (29) 0 (0)
Hematuria 1 (14) 1 (50)
Oral herpes 1 (14) 1 (50)
Arthropod bite 1 (14) 0 (0)
Chest discomfort 1 (14) 0 (0)
Dermatitis contact 1 (14) 0 (0)
Flatulence 1 (14) 0 (0)
Gastroenteritis 1 (14) 0 (0)
Influenza like illness 1 (14) 0 (0)
Injection site erythema 1 (14) 0 (0)
Mouth ulceration 1 (14) 0 (0)
Pain in extremity 1 (14) 0 (0)
Pharyngitis 1 (14) 0 (0)
Productive cough 1 (14) 0 (0)
Rash 1 (14) 0 (0)
Tension headache 1 (14) 0 (0)
Toothache 1 (14) 0 (0)
Vessel puncture site hematoma 1 (14) 0 (0)
Data are presented as No. (%) of patients experiencing the TEAE. The following TEAEs
occurred in placebo in only 1 (50%) subject each: bronchitis, headache, injection site
hemorrhage, and nasal congestion. MedDRA, Medical Dictionary for Regulatory Activities;
TEAE, treatment-emergent adverse event.
CGRP-receptor antagonist telcagepant, an extensive workup
was performed to identify the cause of the mixed picture of
cholestatic and hepatocellular changes. It was concluded that the
concomitant intake of ciprofloxacin, prescribed together with
paracetamol and ibuprofen for the treatment of a urinary tract
infection, was the most likely cause During the multiple-dose
phase, all clinical laboratory parameters were within normal
ranges, including liver function tests.
ADA was assessed predose and at 28 and 42 days
after drug administration in the single dose study. Eleven
(26%) of galcanezumab-treated subjects demonstrated treatment
emergent-ADA (three of whom had pre-existing that increased
in titer after dosing), with low titers between 1:10 and 1:80. These
were 4, 5, 1, and 1 subjects at single doses of 5, 25, 75, and 600mg,
respectively. No dose response was demonstrated, and doses of 1
and 200 mg did not demonstrate detectable ADA. With repeat
biweekly dosing at 150 mg dose, ADA was assessed predose and
on day 50, 71, and 176. No ADA was detected on day 50 and
71, while TE-ADA was detectable in 4 (57%) of galcanezumab-
treated subjects with a titer between 1:20 and 1:160 on day 172.
Although limited to this small number of subjects, the presence of
ADA had no obvious effect on PK (serum concentrations) or PD
(inhibition of capsaicin-induced DBF) compared with subjects
who had no detectable ADA titers (data shown for multiple-dose
cohort, Table 5).
TABLE 5 | The relationship between galcanezumab serum concentration, ADA
titer and capsaicin-induced DBF upon four biweekly galcanezumab dose
administration.
Subject ADA
Titer
Serum
Galcanezumab
(ng/mL)
DBF
Pre-
capsaicin
DBF
Post-
capsaisin
Fold
increase
701 ND 1,765 0.48 2.32 4.8
703 1:20 2,338 0.64 2.54 4.0
704 1:40 4,012 0.65 1.00 1.5
705 1:40 1,935 0.75 2.13 2.8
706 ND 2,599 0.75 1.66 2.2
707 ND 2,145 0.59 1.35 2.3
709 1:160 2,795 0.91 2.91 3.2
PK, ADA, and DBF measurements shown are on Day 176 from the beginning of dosing,
133 days after the last galcanezumab dose administration.
ADA, Anti-drug antibodies; DBF, dermal blood flow; ND, not detected; PK,
pharmacokinetics.
Pharmacokinetics
Serum concentration-time curves of galcanezumab are provided
in Figure 2. PK results following single-dose SC administration
indicate that there was an extended period of absorption, with
a median time to peak concentration (Tmax) between Day 7
and 14 (Table 6). Cmax and the area under the concentration-
time curve from dosing to infinity (AUC(0−∞)) were generally
dose proportional over the full dose range (1 and 600 mg). The
mean serum half-life (t1/2) of galcanezumab was similar at all
dose levels at 25–30 days. PK results following four consecutive
doses of 150 mg administered with a 14-day dosing interval were,
for the most part, as predicted from single-dose administration.
A 3.5-fold accumulation of drug concentrations was observed
after the fourth dose but had not reached steady state. The
median Tmax was 3 days and was much shorter than the 7–
14 day medians observed after single-dose administration. The
geometric mean t1/2 was 31.9 days, which was slightly longer but
consistent with the mean t1/2 observed after single doses.
Pharmacodynamics
Single-dose administration of galcanezumab demonstrated a
dose-dependent inhibition of capsaicin-induced DBF starting at
5 mg between Day 28 and 42. At doses of 75, 200, and 600mg, the
effect was near maximal on Day 3, and remained maximal until
Day 42, the last assessment following single-dose administration
(Figure 3). After four consecutive doses of 150 mg, the induction
of DBF by capsaicin was increasingly inhibited (Figure 4). The
inhibition was sustained for up to 130 days after the last dose of
galcanezumab. Themaximummagnitude of the effect was similar
to the effect of a single dose of 600 mg (Figure 3).
Further, galcanezumab demonstrates inhibition of capsaicin-
induced DBF in a robust concentration-response relationship
when compared with serum concentrations of galcanezumab
(Figure 4). The extended period of inhibition is demonstrated as
the serum concentrations steadily decrease; this result suggests
that a concentration threshold for a maximal inhibitory effect is
exceeded.
In the 1–600 mg dose range, single subcutaneous doses of
galcanezumab did not influence the AIx@HR75 as a measure
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FIGURE 2 | Mean serum galcanezumab concentration profiles over time by dose cohort after single (left) and multiple (right) biweekly dose administration.
TABLE 6 | Mean (±SD) pharmacokinetic parameters of galcanezumab by dose
cohort.
Dose
(mg)
Frequency t1/2,
days
Tmax,
daysa
Cmax,
ng/mL
AUC,
ng·day/mLb
1 Single dose 27.7
(5.1)
13
(7–15)
97.46
(20.91)
4746
(562)
5 Single dose 25.1
(3.7)
14
(7–15)
425.8
(155.4)
20,510
(6,440)
25 Single dose 29.6
(5.7)
7
(4–39)
2,147
(843.8)
96,260
(29,140)
75 Single dose 28.2
(4.4)
7
(2–14)
6,449
(2,782)
280,900
(93,800)
200 Single dose 28.4
(7.1)
7
(4–13)
14,650
(5,366)
663,600
(242,900)
600 Single dose 30.3
(4.6)
7
(4–27)
45,990
(10 060)
2,290 000
(222,900)
150 Four biweekly
dosesc
32.0
(3.0)
3
(1–14)
37,210
(5,793)
1,959,000
(454,700)
Cohort are the 7 subjects administered galcanezumab.
aData are presented as median (range of values from individual subjects).
bAUC(0–∞) for single dose, and AUC over the 2 week dosing period for multiple dose.
cParameters are reported for pharmacokinetic profile after the fourth/last dose
administration; note that steady state was yet to be achieved after the last dose.
AUC(0−∞)inf , area under the concentration-time curve from dosing to infinity; Cmax , peak
serum concentration; t1/2, serum half-life; Tmax , time to peak concentration.
of arterial stiffness and wave reflection. Changes in AIx@HR75
did not appear to be significant on any day of assessment, at
any dose. Additionally, on Day 14, estimates of the differences
in least-squares means were not significant at any dose level
(Table 7).
DISCUSSION
This study primarily reports on the safety and tolerability of
galcanezumab in healthy male subjects following single and
repeated SC injections. Overall, galcanezumab was well tolerated
as either a single dose ranging from 1 to 600 mg or as four
consecutive doses of 150 mg administered every other week.
As secondary objectives, the PK and PD (i.e., inhibition of
capsaicin-induced DBF) of galcanezumab were evaluated. Over
the dose range tested, galcanezumab exposure increased in
proportion to dose, signifying linear PK. In addition, a robust,
durable, and dose-dependent inhibition of capsaicin-induced
DBF was observed. Consequently, the clinical development of
galcanezumab was continued as a prophylactic therapy for
migraine.
Galcanezumab is a fully humanized monoclonal antibody
that potently and selectively binds to CGRP. Monoclonal
antibodies are particularly attractive tools for preventative
treatment because they exhibit a lack of off-target toxicity,
a long elimination half-life, and clearance by proteolysis.
Because galcanezumab is not metabolized by liver enzymes,
drug–drug interactions are very unlikely. Taken together, these
characteristics should translate into a favorable tolerability profile
and patient adherence, and with few contraindications for the
intended indication of migraine prevention.
With respect to safety and tolerability of galcanezumab, there
was no dose-dependent difference in either type or frequency
of treatment-emergent AEs and no clinically meaningful
difference when compared with placebo. Although one subject
developed liver function abnormalities in the single-dose part
of the study, it was likely due to the concomitant intake
of ciprofloxacin, prescribed together with paracetamol and
ibuprofen. Acute cholestatic hepatitis, as observed in this
subject, is an uncommon condition which has previously been
reported as a rare idiosyncratic response to ciprofloxacin.
In this case, galcanezumab had been administered almost 3
months prior to the incident at a very low dose (5 mg),
which, after three elimination half-lives, was almost completely
cleared from the body. This case was therefore considered
to be related to ciprofloxacin which was supported by the
subject’s complete recovery after stopping the antibiotic. So far,
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there is no indication for galcanezumab, or for any of the
monoclonal antibodies interfering with the CGRP pathway, to
cause hepatotoxicity. Therefore, inhibition of this pathway does
not seem to be directly linked to hepatotoxicity.
FIGURE 3 | Mean profiles of the capsaicin-induced dermal blood flow
changes over time (days after galcanezumab administration) for each
single-dose and multiple-dose group. Dermal blood flow is presented as
arbitrary perfusion units as determined by HR-LDPI system software (Periscan
PIMII; Perimed, Sweden).
Another possible safety concern is the potential but unclear
role of CGRP as a vasodilator in maintaining cardiovascular
homeostasis, raising concerns around the cardiovascular
safety of compounds interfering with the CGRP pathway
(MaassenVanDenBrink et al., 2016). Because of this, in addition
to the traditional cardiovascular safety parameters (i.e., blood
pressure, heart rate, and ECG), PWA was included in this
study as an exploratory safety parameter to evaluate the impact
of galcanezumab on changes in arterial stiffness. Based on
PWA, galcanezumab did not affect resting vascular tone. This
observation is consistent with earlier findings suggesting that
inhibition of the effects of CGRP by blocking the receptor
can potently inhibit CGRP-dependent cutaneous vasodilation
induced by capsaicin without affecting arterial stiffness under
basal conditions (Petersen et al., 2005a; Van der Schueren et al.,
2008, 2011). During the course of both parts of the study,
there were no notable dose-related trends or changes in ECG
parameters relative to predose or placebo. Vital signs data did
not reveal any safety concerns, and no relevant cardiovascular
AEs related to galcanezumab were reported. These findings are
consistent with non-clinical and clinical experience with CGRP
antagonists so far and continue to support the cardiovascular
safety of these compounds (Iovino et al., 2004; Petersen et al.,
2005a,b; Zeller et al., 2008). This is in contrast to current
therapies used for the treatment of migraine headache, in
particular the ergot alkaloids and the triptans, which both
increase blood pressure and arterial stiffness and are therefore
formally contraindicated in patients with a higher risk for
cerebrovascular or cardiovascular events (de Hoon et al., 2000,
2001; Vanmolkot and de Hoon, 2006; Depré et al., 2013).
FIGURE 4 | Mean serum concentrations of galcanezumab (±standard error of the mean) and fold change induction by capsaicin of dermal blood flow from baseline
for repeat administration of 150 mg galcanezumab (Days 1, 14, 28, and 42).
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TABLE 7 | Difference of AIx@HR75 between galcanezumab and placebo in
change from predose by dose group on Day 14 after single subcutaneous
injections to healthy subjects.
Dose group Mean change 95% CI P-value
Galcanezumab 1 mg–placebo −4.301 −13.394, 4.791 0.3445
Galcanezumab 5 mg–placebo −2.051 −10.605, 6.502 0.6303
Galcanezumab 25 mg–placebo −1.605 −10.718, 7.508 0.7235
Galcanezumab 75 mg–placebo −0.807 −8.979, 7.366 0.8428
Galcanezumab 200 mg–placebo 1.301 −7.274, 9.875 0.7606
Galcanezumab 600 mg–placebo −0.375 −8.531, 7.781 0.9264
AIx@HR75, augmentation index at heart rate equal to 75; CI, confidence interval.
The safety of galcanezumab is further supported by more
recent data collected in a Phase II study of 218 migraine
patients, 108 of whom received 150 mg of galcanezumab every
2 weeks for 12 weeks (Dodick et al., 2014b). The results of
that study over longer repeated exposure to galcanezumab
demonstrated no clinically relevant drug-related changes in any
safety parameters. In more general terms, ongoing studies with
the various monoclonal antibodies directed against CGRP as a
ligand (i.e., galcanezumab, eptinezumab, and fremanezumab),
as well as against the CGRP receptor (erenumab), are building
evidence of both hepatic and cardiovascular safety (Iovino et al.,
2004; Olesen et al., 2004; Petersen et al., 2005a,b; Van der
Schueren et al., 2011).
A secondary objective of the present study was aimed
at establishing a maximal well-tolerated, safe dose suitable
for testing in a Phase IIa proof-of-concept study. While a
maximum tolerated dose was not determined, the maximum
feasible or practical dose was determined. Further, the long
terminal elimination half-life of galcanezumab of over 30 days
is characteristic for mAbs and suitable for its intended use as a
prophylactic treatment for migraine.
The capsaicin-induced DBF assay was integrated as a
pharmacodynamic biomarker to facilitate dose selection. Given
the pivotal role of CGRP in the increase in DBF following
the local application of capsaicin to the skin, inhibition of
this response has been used previously to provide evidence of
proof of mechanism for CGRP-blocking therapeutics. In this
study, galcanezumab showed a robust and durable inhibition of
capsaicin-induced DBF after both single and repeated injections.
Based on extensive modeling of the PK-PD relationship, a
Q2W (i.e., every other week) dose of 150 mg of galcanezumab
was selected for the Phase II proof-of-concept study, which
confirmed the prophylactic efficacy of galcanezumab in migraine
(Vermeersch et al., 2015).
In conclusion, based on all available data from this Phase I
study demonstrating safety, tolerability, an attractive PK profile,
and proof of mechanism, further development of galcanezumab
for the prevention of migraine is warranted.
AUTHOR CONTRIBUTIONS
DM and JdH: contributed to the conception, design, and
acquisition of data for this work, and contributed to the
drafting of the manuscript and to the critical revision of the
manuscript for important intellectual content. EC: contributed
to the conception, design, interpretation of data for this work,
and has contributed to the critical revision of the manuscript
for important intellectual content. CV and AVH: contributed
to the acquisition and interpretation of data for this work,
and contributed to the critical revision of the manuscript for
important intellectual content. ER, JS, DG, and TS: contributed
to the design and interpretation of data for this work, and
contributed to the critical revision of the manuscript for
important intellectual content.
FUNDING
The trial was sponsored by Eli Lilly and Company and Arteaus
Therapeutics.
OTHER INFORMATION
The trial is registered at ClinicalTrials.gov (NCT 01337596).
ACKNOWLEDGMENTS
The authors thank the staff of the Centre for Clinical
Pharmacology, most importantly Steve Vermeersch, Jo Van
Effen, and Marissa Herbots, for assisting in the experiments
and data collection. Medical writing support was provided
by Steve Sweeney of Arteaus Therapeutics. This work was
funded by Eli Lilly and Company and Arteaus Therapeutics.
In addition, the authors thank John Polzer and Jeff Miller of
Eli Lilly and Company and Sarah Becker-Marrero and Michael
Ossipov of inVentiv Health Clinical, LLC, for their help with
writing, editing, and formatting the manuscript. Eli Lilly and
Company contracted inVentiv Health Clinical, LLC, for writing
and editorial services.
REFERENCES
Asghar, M. S., Hansen, A. E., Amin, F. M., van der Geest, R. J., Koning, P. V.,
Larsson, H. B., et al. (2011). Evidence for a vascular factor in migraine. Ann.
Neurol. 69, 635–645. doi: 10.1002/ana.22292
Bigal, M. E., and Lipton, R. B. (2006). Modifiable risk factors for migraine
progression. Headache 46, 1334–1343. doi: 10.1111/j.1526-4610.2006.00577.x
Bigal, M. E., and Lipton, R. B. (2008). Concepts and mechanisms of migraine
chronification. Headache 48, 7–15. doi: 10.1111/j.1526-4610.2007.00969.x
Bigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma,
Y., Yang, R., et al. (2015a). Safety, tolerability, and efficacy of TEV-
48125 for preventive treatment of high-frequency episodic migraine:
a multicentre, randomised, double-blind, placebo-controlled, phase
2b study. Lancet Neurol. 14, 1081–1090. doi: 10.1016/S1474-4422(15)
00249-5
Bigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E.
L., Diener, H. C., et al. (2015b). Safety, tolerability, and efficacy of
TEV-48125 for preventive treatment of chronic migraine: a multicentre,
Frontiers in Pharmacology | www.frontiersin.org 9 October 2017 | Volume 8 | Article 740
Monteith et al. Galcanezumab in Healthy Volunteers (Phase I)
randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol.
14, 1091–1100. doi: 10.1016/S1474-4422(15)00245-8
Buntinx, L., Vermeersch, S., and de Hoon, J. (2015). Development of anti-migraine
therapeutics using the capsaicin-induced dermal blood flow model. Br. J. Clin.
Pharmacol. 80, 992–1000. doi: 10.1111/bcp.12704
de Hoon, J. N., Poppe, K. A., Thijssen, H. H., Struijker-Boudier, H. A., and
Van Bortel, L. M. (2001). Dihydroergotamine: discrepancy between arterial,
arteriolar and pharmacokinetic data. Br. J. Clin. Pharmacol. 52, 45–51.
doi: 10.1046/j.0306-5251.2001.01415.x
de Hoon, J. N., Willigers, J. M., Troost, J., Struijker-Boudier, H. A., and
Van Bortel, L. M. (2000). Vascular effects of 5-HT1B/1D-receptor agonists
in patients with migraine headaches. Clin. Pharmacol. Ther. 68, 418–426.
doi: 10.1067/mcp.2000.110502
Depré, M., Macleod, C., Palcza, J., Behm, M., de Lepeleire, I., Han,
T., et al. (2013). Lack of hemodynamic interaction between CGRP-
receptor antagonist telcagepant (MK-0974) and sumatriptan: results from
a randomized study in patients with migraine. Cephalalgia 33, 1292–1301.
doi: 10.1177/0333102413494272
Diener, H. C., Dodick, D. W., Goadsby, P. J., Lipton, R. B., Olesen, J., and
Silberstein, S. D. (2012). Chronic migraine—classification, characteristics and
treatment. Nat. Rev. Neurol. 8, 162–171. doi: 10.1038/nrneurol.2012.13
Dodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina,
M., et al. (2014a). Safety and efficacy of ALD403, an antibody to calcitonin gene-
related peptide, for the prevention of frequent episodic migraine: a randomised,
double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 13,
1100–1107. doi: 10.1016/S1474-4422(14)70209-1
Dodick, D. W., Goadsby, P. J., Spierings, E. L., Scherer, J. C., Sweeney, S. P.,
and Grayzel, D. S. (2014b). Safety and efficacy of LY2951742, a monoclonal
antibody to calcitonin gene-related peptide, for the prevention of migraine: a
phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol.
13, 885–892. doi: 10.1016/S1474-4422(14)70128-0
Durham, P. L., and Vause, C. V. (2010). Calcitonin gene-related peptide (CGRP)
receptor antagonists in the treatment of migraine. CNS Drugs 24, 539–548.
doi: 10.2165/11534920-000000000-00000
Eftekhari, S., and Edvinsson, L. (2011). Calcitonin gene-related peptide (CGRP)
and its receptor components in human and rat spinal trigeminal nucleus and
spinal cord at C1-level. BMC Neurosci. 12:112. doi: 10.1186/1471-2202-12-112
Geppetti, P., Rossi, E., Chiarugi, A., and Benemei, S. (2012). Antidromic
vasodilatation and the migraine mechanism. J. Headache Pain 13, 103–111.
doi: 10.1007/s10194-011-0408-3
Goadsby, P. J., Edvinsson, L., and Ekman, R. (1988). Release of vasoactive
peptides in the extracerebral circulation of humans and the cat during
activation of the trigeminovascular system. Ann. Neurol. 23, 193–196.
doi: 10.1002/ana.410230214
Goadsby, P. J., Edvinsson, L., and Ekman, R. (1990). Vasoactive peptide release
in the extracerebral circulation of humans during migraine headache. Ann.
Neurol. 28, 183–187. doi: 10.1002/ana.410280213
Hansen, J. M., Hauge, A. W., Olesen, J., and Ashina, M. (2010). Calcitonin gene-
related peptide triggers migraine-like attacks in patients with migraine with
aura. Cephalalgia 30, 1179–1186. doi: 10.1177/0333102410368444
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan,
X., et al. (2014). Randomized controlled trial of the CGRP receptor
antagonist telcagepant for migraine prevention. Neurology 83, 958–966.
doi: 10.1212/WNL.0000000000000771
Ho, T. W., Edvinsson, L., and Goadsby, P. J. (2010). CGRP and its receptors
provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6,
573–582. doi: 10.1038/nrneurol.2010.127
Ho, T. W., Ferrari, M. D., Dodick, D. W., Galet, V., Kost, J., Fan, X., et al. (2008).
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of
calcitonin gene-related peptide receptor, compared with zolmitriptan for acute
migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet
372, 2115–2123. doi: 10.1016/S0140-6736(08)61626-8
Iovino,M., Feifel, U., Yong, C. L.,Wolters, J. M., andWallenstein, G. (2004). Safety,
tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small
molecule calcitonin gene-related peptide receptor antagonist, following single
intravenous administration in healthy volunteers. Cephalalgia 24, 645–656.
doi: 10.1111/j.1468-2982.2004.00726.x
Juhasz, G., Zsombok, T., Jakab, B., Nemeth, J., Szolcsanyi, J., and Bagdy,
G. (2005). Sumatriptan causes parallel decrease in plasma calcitonin
gene-related peptide (CGRP) concentration and migraine headache
during nitroglycerin induced migraine attack. Cephalalgia 25, 179–183.
doi: 10.1111/j.1468-2982.2005.00836.x
Juhasz, G., Zsombok, T., Modos, E. A., Olajos, S., Jakab, B., Nemeth, J., et al. (2003).
NO-induced migraine attack: strong increase in plasma calcitonin gene-related
peptide (CGRP) concentration and negative correlation with platelet serotonin
release. Pain 106, 461–470. doi: 10.1016/j.pain.2003.09.008
Karsan, N., and Goadsby, P. J. (2015). Calcitonin gene-related peptide and
migraine. Curr. Opin. Neurol. 28, 250–254. doi: 10.1097/WCO.00000000
00000191
Lassen, L. H., Haderslev, P. A., Jacobsen, V. B., Iversen, H. K., Sperling, B., and
Olesen, J. (2002). CGRP may play a causative role in migraine. Cephalalgia 22,
54–61. doi: 10.1046/j.1468-2982.2002.00310.x
Lennerz, J. K., Rühle, V., Ceppa, E. P., Neuhuber, W. L., Bunnett, N. W., Grady,
E. F., et al. (2008). Calcitonin receptor-like receptor (CLR), receptor activity-
modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP)
immunoreactivity in the rat trigeminovascular system: differences between
peripheral and central CGRP receptor distribution. J. Comp. Neurol. 507,
1277–1299. doi: 10.1002/cne.21607
Lipton, R. B. (2011). Chronic migraine, classification, differential diagnosis,
and epidemiology. Headache 51 (Suppl. 2), 77–83. doi: 10.1111/j.1526-4610.
2011.01954.x
MaassenVanDenBrink, A., Meijer, J., Villalón, C. M., and Ferrari, M. D. (2016).
Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol. Sci. 37,
779–788. doi: 10.1016/j.tips.2016.06.002
Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud,
C., et al. (2012). Disability-adjusted life years (DALYs) for 291 diseases and
injuries in 21 regions, 1990-2010: a systematic analysis for the Global burden
of disease study 2010. Lancet 380, 2197–2223. doi: 10.1016/S0140-6736(12)
61689-4
Olesen, J., Diener, H. C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U.,
et al. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096
BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104–1110.
doi: 10.1056/NEJMoa030505
Petersen, K. A., Birk, S., Lassen, L. H., Kruuse, C., Jonassen, O., Lesko, L.,
et al. (2005a). The CGRP-antagonist, BIBN4096BS does not affect cerebral
or systemic haemodynamics in healthy volunteers. Cephalalgia 25, 139–147.
doi: 10.1111/j.1468-2982.2004.00830.x
Petersen, K. A., Lassen, L. H., Birk, S., Lesko, L., and Olesen, J. (2005b).
BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-
induced headache and extracerebral artery dilatation. Clin. Pharmacol. Ther.
77, 202–213. doi: 10.1016/j.clpt.2004.10.001
Sinclair, S. R., Kane, S. A., Van der Schueren, B. J., Xiao, A., Willson, K. J., Boyle,
J., et al. (2010). Inhibition of capsaicin-induced increase in dermal blood flow
by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br. J. Clin.
Pharmacol. 69, 15–22. doi: 10.1111/j.1365-2125.2009.03543.x
Sun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., et al.
(2016). Safety and efficacy of AMG 334 for prevention of episodic migraine: a
randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15,
382–390. doi: 10.1016/S1474-4422(16)00019-3
Van der Schueren, B. J., Blanchard, R., Murphy, M. G., Palcza, J., De
Lepeleire, I., Van Hecken, A., et al. (2011). The potent calcitonin gene-
related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-
induced vasodilation in healthy men. Br. J. Clin. Pharmacol. 71, 708–717.
doi: 10.1111/j.1365-2125.2010.03869.x
Van der Schueren, B. J., de Hoon, J. N., Vanmolkot, F. H., Van Hecken,
A., Depre, M., Kane, S. A., et al. (2007). Reproducibility of the capsaicin-
induced dermal blood flow response as assessed by laser Doppler perfusion
imaging. Br. J. Clin. Pharmacol. 64, 580–590. doi: 10.1111/j.1365-2125.2007.
02939.x
Van der Schueren, B. J., Rogiers, A., Vanmolkot, F. H., Van Hecken, A.,
Depré, M., Kane, S. A., et al. (2008). Calcitonin gene-related peptide8-37
antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human
in vivo pharmacodynamic model. J. Pharmacol. Exp. Ther. 325, 248–255.
doi: 10.1124/jpet.107.133868
Frontiers in Pharmacology | www.frontiersin.org 10 October 2017 | Volume 8 | Article 740
Monteith et al. Galcanezumab in Healthy Volunteers (Phase I)
Vanmolkot, F. H., and de Hoon, J. N. (2006). Acute effects of sumatriptan on aortic
blood pressure, stiffness, and pressure waveform. Clin. Pharmacol. Ther. 80,
85–94. doi: 10.1016/j.clpt.2006.03.011
Vanmolkot, F., Van der Schueren, B., and de Hoon, J. (2006). Sumatriptan
causes parallel decrease in plasma CGRP concentration and migraine headache
during nitroglycerin-induced migraine attack. Cephalalgia 26, 1037–1038.
doi: 10.1111/j.1468-2982.2006.01133_1.x
Vermeersch, S., Benschop, R. J., Van Hecken, A., Monteith, D., Wroblewski,
V. J., Grayzel, D., et al. (2015). Translational pharmacodynamics of
calcitonin gene-related peptidemonoclonal antibody LY2951742 in a capsaicin-
induced dermal blood flow model. J. Pharmacol. Exp. Ther. 354, 350–357.
doi: 10.1124/jpet.115.224212
Warfvinge, K., and Edvinsson, L. (2013). Pearls and pitfalls in neural
CGRP immunohistochemistry. Cephalalgia 33, 593–603. doi: 10.1177/0333102
412472072
Zeller, J., Poulsen, K. T., Sutton, J. E., Abdiche, Y. N., Collier, S.,
Chopra, R., et al. (2008). CGRP function-blocking antibodies inhibit
neurogenic vasodilatation without affecting heart rate or arterial blood
pressure in the rat. Br. J. Pharmacol. 155, 1093–1103. doi: 10.1038/bjp.
2008.334
Conflict of Interest Statement: ER and EC are employees of Eli Lilly and
Company. DM and JS were employees of Eli Lilly and Company at the time
the study was conducted. JdH acted as Principal Investigator, for which the
university received research grants from Abide, Amgen, Galderma, Genentech,
GlaxoSmithKline, Janssen Research & Development, Lilly Chorus, MSD, Novartis,
Sanofi Pasteur, UCB, and Vertex; and acted as a consultant for Ablynx, Amgen,
Eli Lilly, Genentech, and UCB. CV acted as Principal Investigator, for which
the University received research grants from AdImmune, GlaxoSmithKline, and
Sanofi Pasteur. DG and TS were employees of Arteaus Therapeutics at the time
of the study. AV declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential conflict
of interest.
Copyright © 2017 Monteith, Collins, Vandermeulen, Van Hecken, Raddad, Scherer,
Grayzel, Schuetz and de Hoon. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 11 October 2017 | Volume 8 | Article 740
